These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 17558098

  • 1. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study.
    Purandare H, Supe A.
    Indian J Med Sci; 2007 Jun; 61(6):347-55. PubMed ID: 17558098
    [Abstract] [Full Text] [Related]

  • 2. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
    Armstrong DG.
    Indian J Med Sci; 2007 Jun; 61(6):324-5. PubMed ID: 17558094
    [No Abstract] [Full Text] [Related]

  • 3. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000 Jun; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 4. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
    Steed DL.
    Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
    [Abstract] [Full Text] [Related]

  • 5. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S.
    Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
    [Abstract] [Full Text] [Related]

  • 6. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N, Maltezos E.
    Clin Interv Aging; 2008 Oct; 3(2):233-40. PubMed ID: 18686746
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH.
    Wound Repair Regen; 1999 Oct; 7(5):335-46. PubMed ID: 10564562
    [Abstract] [Full Text] [Related]

  • 8. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.
    Wound Repair Regen; 2000 Oct; 8(3):162-8. PubMed ID: 10886806
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

  • 10. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.
    Lantis JC, Boone D, Gendics C, Todd G.
    Adv Skin Wound Care; 2009 Apr; 22(4):167-71. PubMed ID: 19325276
    [Abstract] [Full Text] [Related]

  • 11. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
    Landsman A, Agnew P, Parish L, Joseph R, Galiano RD.
    J Am Podiatr Med Assoc; 2010 Apr; 100(3):155-60. PubMed ID: 20479444
    [Abstract] [Full Text] [Related]

  • 12. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group.
    Steed DL, Donohoe D, Webster MW, Lindsley L.
    J Am Coll Surg; 1996 Jul; 183(1):61-4. PubMed ID: 8673309
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [Abstract] [Full Text] [Related]

  • 14. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
    Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP.
    Adv Skin Wound Care; 2005 Jun; 18(5 Pt 1):258-66. PubMed ID: 15942317
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Human epidermal growth factor enhances healing of diabetic foot ulcers.
    Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EY, Kam G, Leung L, Chan CW, Chu CM, Lam EK.
    Diabetes Care; 2003 Jun; 26(6):1856-61. PubMed ID: 12766123
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O, Persson U, Willis M, Odegaard K.
    Pharmacoeconomics; 2001 Jun; 19(7):767-78. PubMed ID: 11548912
    [Abstract] [Full Text] [Related]

  • 19. Comparing the standard surgical dressing with dehydrated amnion and platelet-derived growth factor dressings in the healing rate of diabetic foot ulcer: A randomized clinical trial.
    Mohammadi Tofigh A, Tajik M.
    Diabetes Res Clin Pract; 2022 Mar; 185():109775. PubMed ID: 35149167
    [Abstract] [Full Text] [Related]

  • 20. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS.
    J Foot Ankle Surg; 1999 Mar; 38(3):227-31. PubMed ID: 10384364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.